TTNP - Titan Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Total Revenue
4,002
3,611
5,911
215
15,065
Cost of Revenue
1,155
1,288
538
-
-
Gross Profit
2,847
2,323
5,373
-
-
Operating Expense
19,632
19,167
13,637
14,717
10,722
Operating Income
-16,785
-16,844
-8,264
-14,502
4,343
Net Non Operating Interest Income Expense
-943
-967
-887
-369
37
Other Income Expense
203
1,353
128
564
755
Pretax Income
-17,525
-16,458
-9,023
-14,307
5,135
Net Income Common Stockholders
-17,525
-16,458
-9,308
-14,307
5,135
Average Dilution Earnings
-
0
-134
619
-825
Diluted NI Available to Com Stockholders
-17,525
-16,458
-9,442
-13,688
4,310
Basic EPS
-
0
0
-0.004
0.0015
Diluted EPS
-
0
0
-0.0042
0.0012
Basic Average Shares
-
22,957
11,958
3,534
3,457
Diluted Average Shares
-
22,957
11,958
3,538
3,577
Total Operating Income as Reported
-16,785
-16,844
-8,264
-14,502
4,343
Total Expenses
20,787
20,455
14,175
14,717
10,722
Net Income from Continuing & Discontinued Operation
-17,525
-16,458
-9,023
-14,307
5,135
Normalized Income
-17,525
-17,794
-9,157
-14,926
4,682
Net Interest Income
-943
-967
-887
-369
37
EBIT
-17,935
-16,844
-8,264
-14,502
4,343
EBITDA
-17,689
-
-
-
-
Reconciled Cost of Revenue
1,155
1,288
538
-
-
Reconciled Depreciation
246
244
380
417
377
Net Income from Continuing Operation Net Minority Interest
-17,525
-16,458
-9,023
-14,307
5,135
Total Unusual Items Excluding Goodwill
-
1,336
134
619
755
Total Unusual Items
-
1,336
134
619
755
Normalized EBITDA
-17,689
-17,936
-8,018
-14,704
3,965
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
302